Cadila Healthcare Ltd on Thursday said group firm Zydus has received final approval from the US health regulator to market its generic version of Vigabatrin tablets to treat babies with infantile spasms and epilepsy in combination with other medications.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3qIk5yk
via IFTTT
0 comments:
Post a Comment